<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-037513</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Nonsmall cell lung cancer in stage IA: mortality patterns after surgery</dc:title>
<dc:description xml:lang="en">OBJECTIVE: To determine the causes of death in patients        treated surgically for nonsmall cell lung cancer (NSCLC) in        stage IA and to evaluate the impact on survival of not        performing systematic lymph node dissection and of the        number of nodes resected.        PATIENTS AND METHODS: The study sample consisted of        156 patients operated on for NSCLC and classified in stage        IA according to TNM staging. Only palpable or visible        lymph nodes were dissected. Kaplan-Meier survival curves        were compared using a log-rank test.        RESULTS: At the end of the study, 85 (54.5%) patients had        died, 67 (42.9%) were alive, and 4 (2.5%) were lost to follow        up. Twenty-three (14.7%) died from a recurrence of        NSCLC: 2 with local tumors (1.2%), 2 with mediastinal        node involvement (1.2%), and 19 (12.1%) with distant        metastasis. The cause of death was unrelated to NSCLC in        62 (39.7%) cases: 33 (21.1%) had a new tumor, 18 of which        were bronchogenic, and 29 (18.5%) had nonmalignant        disease. The 5-year survival rate was 81.4%. The rate was        88.9% among patients from whom no lymph nodes were        excised and 79.9% among those with node excision, although        the difference was not statistically significant (P=.4073).        CONCLUSIONS: Our experience suggests that neither the        fact of not performing systematic lymph node dissection nor        the number of nodes resected has an impact on survival. A        substantial number of patients died of causes unrelated to        the NSCLC for which they had been treatedOBJECTIVE: To determine the causes of death in patients        treated surgically for nonsmall cell lung cancer (NSCLC) in        stage IA and to evaluate the impact on survival of not        performing systematic lymph node dissection and of the        number of nodes resected.        PATIENTS AND METHODS: The study sample consisted of        156 patients operated on for NSCLC and classified in stage        IA according to TNM staging. Only palpable or visible        lymph nodes were dissected. Kaplan-Meier survival curves        were compared using a log-rank test.        RESULTS: At the end of the study, 85 (54.5%) patients had        died, 67 (42.9%) were alive, and 4 (2.5%) were lost to follow        up. Twenty-three (14.7%) died from a recurrence of        NSCLC: 2 with local tumors (1.2%), 2 with mediastinal        node involvement (1.2%), and 19 (12.1%) with distant        metastasis. The cause of death was unrelated to NSCLC in        62 (39.7%) cases: 33 (21.1%) had a new tumor, 18 of which        were bronchogenic, and 29 (18.5%) had nonmalignant        disease. The 5-year survival rate was 81.4%. The rate was        88.9% among patients from whom no lymph nodes were        excised and 79.9% among those with node excision, although        the difference was not statistically significant (P=.4073).        CONCLUSIONS: Our experience suggests that neither the        fact of not performing systematic lymph node dissection nor        the number of nodes resected has an impact on survival. A        substantial number of patients died of causes unrelated to        the NSCLC for which they had been treated</dc:description>
<dc:creator>García Zarza, A</dc:creator>
<dc:creator>Calvo, V</dc:creator>
<dc:creator>Padilla, J</dc:creator>
<dc:creator>Peñalver, J. C</dc:creator>
<dc:creator>Cerón, J</dc:creator>
<dc:creator>Pastor, J</dc:creator>
<dc:creator>Escrivá, J</dc:creator>
<dc:creator>Blasco, E</dc:creator>
<dc:creator>Jordá, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVO: Determinar las causas de mortalidad en los pacientes        operados de un carcinoma broncogénico no anaplásico        de células pequeñas (CBNACP) en estadio IA y el impacto        que tiene en la supervivencia el hecho de no realizar        una disección ganglionar sistemática, así como el número de        ganglios resecados.        PACIENTES Y MÉTODOS: Se estudió a 156 pacientes operados        de un CBNACP y clasificados en el estadio IA de acuerdo        con el sistema tumor, nódulo, metástasis patológico. Sólo        se extirparon los ganglios palpables o visibles. La supervivencia        se analizó con el método de Kaplan-Meier y las curvas        se compararon mediante el test de rangos logarítmicos.        RESULTADOS: Al finalizar el estudio, 85 (54,5%) pacientes        habían fallecido, 67 (42,9%) estaban vivos y 4 (2,5%) se habían        perdido en el seguimiento. Veintitrés (14,7%) pacientes        fallecieron por recidiva del CBNACP: 2 por recidiva local        (1,2%), otros 2 en el ganglio mediastínico (1,2%) y 19 (12,1%)        por metástasis a distancia. En 62 (39,7%) de los casos la causa        de la muerte no estuvo relacionada con el CBNACP: 33        (21,1%) fallecieron por aparición de un nuevo cáncer, 18 de        los cuales fueron broncogénicos, y 29 (18,5%) por enfermedades        no tumorales. La supervivencia a los 5 años fue del        81,4%. Cuando no se extirpó ningún ganglio, la supervivencia        fue del 88,9%, mientras que cuando se extirparon fue del        79,9%, aunque la diferencia no fue significativa (p = 0,4073).        CONCLUSIONES: En nuestra experiencia, ni el hecho de no        realizar disección ganglionar sistemática ni el número de        ganglios extirpados han tenido una influencia en la supervivencia        a los 5 años. Un número considerable de pacientes falleció        de una causa distinta del CBNACP del que se les había        operado</dc:description>
<dc:source>Arch Bronconeumol;41(4): 180-184, abr. 2005. ilus, tab</dc:source>
<dc:identifier>ibc-037513</dc:identifier>
<dc:title xml:lang="es">Carcinoma broncogénico no anaplásico de células pequeñas en estadio IA. Cirugía y patrones de mortalidad</dc:title>
<dc:subject>^d31722^s22053</dc:subject>
<dc:subject>^d8352^s22053</dc:subject>
<dc:subject>^d2326^s22053</dc:subject>
<dc:subject>^d28637</dc:subject>
<dc:subject>^d28604</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2326^s22047</dc:subject>
<dc:subject>^d31722^s22047</dc:subject>
<dc:subject>^d8374</dc:subject>
<dc:subject>^d8352^s22047</dc:subject>
<dc:subject>^d9560</dc:subject>
<dc:type>article</dc:type>
<dc:date>200504</dc:date>
</metadata>
</record>
</ibecs-document>
